US Stock MarketDetailed Quotes
RAPP Rapport Therapeutics
- 22.480
- +0.140+0.63%
Trading Nov 27 11:50 ET
822.24MMarket Cap-11446P/E (TTM)
23.950High22.360Low7.96KVolume22.520Open22.340Pre Close180.86KTurnover0.09%Turnover RatioLossP/E (Static)36.58MShares29.74052wk High2.54P/B206.82MFloat Cap16.55052wk Low--Dividend TTM9.20MShs Float29.740Historical High--Div YieldTTM7.12%Amplitude16.550Historical Low22.729Avg Price1Lot Size
Rapport Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||
| Gross profit | ||||||||
| Operating expense | 126.27%21.64M | 213.73%20.8M | 229.30%17.09M | 36.18M | 14.79M | 9.56M | 6.63M | 5.19M |
| Selling and administrative expenses | 207.31%6.1M | 167.73%5.11M | 255.26%4.59M | --8.18M | --3M | --1.98M | --1.91M | --1.29M |
| -General and administrative expense | 207.31%6.1M | 167.73%5.11M | 255.26%4.59M | --8.18M | --3M | --1.98M | --1.91M | --1.29M |
| Research and development costs | 105.05%15.54M | 232.32%15.69M | 220.70%12.5M | --28M | --11.8M | --7.58M | --4.72M | --3.9M |
| Operating profit | -126.27%-21.64M | -213.73%-20.8M | -229.30%-17.09M | -36.18M | -14.79M | -9.56M | -6.63M | -5.19M |
| Net non-operating interest income expense | 379.32%4.1M | 1,112.22%2.68M | 2,320.00%1.82M | 2.53M | 1.38M | 856K | 221K | 75K |
| Non-operating interest income | 379.32%4.1M | 1,112.22%2.68M | 2,320.00%1.82M | --2.53M | --1.38M | --856K | --221K | --75K |
| Non-operating interest expense | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other net income (expense) | -617.48%-7.39M | -1.12M | -94K | -1.03M | ||||
| Other non- operating income (expenses) | ---- | ---- | -617.48%-7.39M | ---1.12M | ---94K | ---- | ---- | ---1.03M |
| Income before tax | -101.39%-17.54M | -182.74%-18.12M | -268.84%-22.67M | -34.78M | -13.51M | -8.71M | -6.41M | -6.15M |
| Income tax | 0 | 0 | 0 | 10K | 6K | 1K | 2K | 1K |
| Net income | -101.37%-17.54M | -182.65%-18.12M | -268.78%-22.67M | -34.79M | -13.52M | -8.71M | -6.41M | -6.15M |
| Net income continuous Operations | -101.37%-17.54M | -182.65%-18.12M | -268.78%-22.67M | ---34.79M | ---13.52M | ---8.71M | ---6.41M | ---6.15M |
| Minority interest income | ||||||||
| Net income attributable to the parent company | -101.37%-17.54M | -182.65%-18.12M | -268.78%-22.67M | -34.79M | -13.52M | -8.71M | -6.41M | -6.15M |
| Preferred stock dividends | ||||||||
| Other preferred stock dividends | ||||||||
| Net income attributable to common stockholders | -101.37%-17.54M | -182.65%-18.12M | -268.78%-22.67M | -34.79M | -13.52M | -8.71M | -6.41M | -6.15M |
| Basic earnings per share | -38.90%-0.5 | -541.54%-1.7 | -269.97%-0.94 | -1.47 | -0.3821 | -0.36 | -0.265 | -0.2541 |
| Diluted earnings per share | -38.90%-0.5 | -541.54%-1.7 | -269.97%-0.94 | -1.47 | -0.3821 | -0.36 | -0.265 | -0.2541 |
| Dividend per share | ||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data